Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02227251
Recruitment Status : Active, not recruiting
First Posted : August 28, 2014
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : December 2020